J. Steven Leeder
Concepts (849)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cytochrome P-450 CYP2D6 | 51 | 2024 | 184 | 8.900 |
Why?
| Pharmacogenetics | 45 | 2023 | 176 | 8.320 |
Why?
| Cytochrome P-450 Enzyme System | 47 | 2024 | 96 | 6.700 |
Why?
| Liver | 38 | 2024 | 126 | 5.980 |
Why?
| Humans | 249 | 2024 | 6896 | 5.720 |
Why?
| Microsomes, Liver | 23 | 2024 | 44 | 3.660 |
Why?
| Pharmacokinetics | 10 | 2021 | 14 | 3.650 |
Why?
| Genotype | 65 | 2024 | 410 | 3.630 |
Why?
| Child | 90 | 2024 | 3364 | 3.540 |
Why?
| Cytochrome P-450 CYP3A | 26 | 2020 | 46 | 3.360 |
Why?
| Pharmaceutical Preparations | 16 | 2024 | 37 | 3.000 |
Why?
| Female | 97 | 2024 | 3525 | 2.970 |
Why?
| Adolescent | 68 | 2024 | 2197 | 2.900 |
Why?
| Male | 94 | 2024 | 3337 | 2.740 |
Why?
| Genetic Variation | 21 | 2024 | 174 | 2.690 |
Why?
| Precision Medicine | 9 | 2019 | 45 | 2.650 |
Why?
| Methotrexate | 12 | 2018 | 30 | 2.430 |
Why?
| Child, Preschool | 51 | 2024 | 1569 | 2.290 |
Why?
| Adult | 50 | 2024 | 1181 | 2.290 |
Why?
| Hypercholesterolemia | 3 | 2024 | 12 | 2.260 |
Why?
| Aryl Hydrocarbon Hydroxylases | 18 | 2024 | 45 | 2.130 |
Why?
| Infant, Newborn | 47 | 2024 | 816 | 2.130 |
Why?
| Models, Biological | 12 | 2024 | 65 | 2.120 |
Why?
| Aging | 9 | 2021 | 39 | 2.080 |
Why?
| Dextromethorphan | 24 | 2022 | 55 | 2.000 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2020 | 23 | 1.990 |
Why?
| Infant | 46 | 2024 | 1446 | 1.970 |
Why?
| Attention Deficit Disorder with Hyperactivity | 4 | 2024 | 18 | 1.950 |
Why?
| Child Development | 10 | 2022 | 44 | 1.940 |
Why?
| Dose-Response Relationship, Drug | 18 | 2020 | 94 | 1.910 |
Why?
| Polymorphism, Single Nucleotide | 23 | 2021 | 348 | 1.880 |
Why?
| Biotransformation | 26 | 2021 | 49 | 1.870 |
Why?
| Atomoxetine Hydrochloride | 5 | 2024 | 10 | 1.850 |
Why?
| Age Factors | 24 | 2024 | 210 | 1.770 |
Why?
| Gene Expression Regulation, Developmental | 10 | 2020 | 51 | 1.750 |
Why?
| Phenotype | 33 | 2022 | 257 | 1.600 |
Why?
| Arthritis, Juvenile | 8 | 2016 | 31 | 1.580 |
Why?
| Cerebral Palsy | 3 | 2023 | 18 | 1.550 |
Why?
| Fetus | 7 | 2018 | 16 | 1.530 |
Why?
| Alleles | 23 | 2023 | 214 | 1.490 |
Why?
| Young Adult | 22 | 2024 | 647 | 1.440 |
Why?
| Alternative Splicing | 5 | 2020 | 18 | 1.380 |
Why?
| Anticonvulsants | 9 | 2018 | 25 | 1.360 |
Why?
| Polymorphism, Genetic | 14 | 2019 | 90 | 1.330 |
Why?
| Proteins | 5 | 2023 | 27 | 1.310 |
Why?
| Polymerase Chain Reaction | 11 | 2015 | 84 | 1.300 |
Why?
| Inactivation, Metabolic | 8 | 2018 | 15 | 1.300 |
Why?
| Adrenergic Uptake Inhibitors | 3 | 2024 | 6 | 1.260 |
Why?
| Analgesics, Opioid | 9 | 2021 | 42 | 1.240 |
Why?
| Drug Dosage Calculations | 5 | 2021 | 16 | 1.230 |
Why?
| Pediatrics | 7 | 2012 | 186 | 1.220 |
Why?
| Carbamazepine | 8 | 2011 | 10 | 1.190 |
Why?
| Biomarkers | 9 | 2023 | 136 | 1.180 |
Why?
| Chromatography, High Pressure Liquid | 16 | 2019 | 40 | 1.160 |
Why?
| Tandem Mass Spectrometry | 8 | 2024 | 20 | 1.120 |
Why?
| Lung | 12 | 2017 | 65 | 1.110 |
Why?
| Membrane Transport Proteins | 8 | 2024 | 16 | 1.110 |
Why?
| Epigenesis, Genetic | 3 | 2016 | 68 | 1.070 |
Why?
| Glucuronosyltransferase | 8 | 2020 | 16 | 1.060 |
Why?
| Middle Aged | 22 | 2024 | 608 | 1.050 |
Why?
| Gene Frequency | 14 | 2016 | 90 | 1.040 |
Why?
| Animals | 32 | 2024 | 729 | 1.040 |
Why?
| Anti-Infective Agents | 3 | 2016 | 21 | 1.020 |
Why?
| Cytochrome P-450 CYP2D6 Inhibitors | 5 | 2020 | 11 | 0.990 |
Why?
| Pravastatin | 3 | 2020 | 7 | 0.970 |
Why?
| Drug Interactions | 9 | 2022 | 32 | 0.970 |
Why?
| Genetic Testing | 7 | 2019 | 87 | 0.960 |
Why?
| Pteroylpolyglutamic Acids | 3 | 2014 | 3 | 0.960 |
Why?
| Folic Acid | 4 | 2019 | 17 | 0.950 |
Why?
| Pregnancy | 14 | 2019 | 216 | 0.950 |
Why?
| RNA, Messenger | 13 | 2018 | 115 | 0.930 |
Why?
| Polyglutamic Acid | 4 | 2011 | 4 | 0.930 |
Why?
| Promoter Regions, Genetic | 5 | 2016 | 49 | 0.930 |
Why?
| Genomics | 5 | 2022 | 101 | 0.910 |
Why?
| Acetaminophen | 8 | 2019 | 18 | 0.900 |
Why?
| Dystonic Disorders | 1 | 2023 | 4 | 0.890 |
Why?
| Dystonia | 1 | 2023 | 8 | 0.890 |
Why?
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2014 | 13 | 0.880 |
Why?
| Folic Acid Antagonists | 2 | 2013 | 2 | 0.860 |
Why?
| Cytochrome P-450 CYP2C19 | 12 | 2024 | 60 | 0.860 |
Why?
| Haplotypes | 9 | 2024 | 91 | 0.860 |
Why?
| Receptors, Steroid | 3 | 2016 | 5 | 0.850 |
Why?
| Indomethacin | 2 | 2022 | 4 | 0.850 |
Why?
| Antipsychotic Agents | 3 | 2020 | 14 | 0.840 |
Why?
| Drug Design | 3 | 2010 | 7 | 0.810 |
Why?
| Drug Hypersensitivity | 7 | 1998 | 19 | 0.800 |
Why?
| Narcotic Antagonists | 1 | 2021 | 3 | 0.800 |
Why?
| Naltrexone | 1 | 2021 | 4 | 0.790 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2022 | 39 | 0.790 |
Why?
| Simvastatin | 2 | 2019 | 10 | 0.780 |
Why?
| Gene Expression Regulation, Enzymologic | 8 | 2016 | 20 | 0.740 |
Why?
| Metabolic Clearance Rate | 8 | 2023 | 18 | 0.740 |
Why?
| Pimozide | 1 | 2020 | 4 | 0.740 |
Why?
| Erythrocytes | 4 | 2014 | 11 | 0.730 |
Why?
| Cytosol | 7 | 2024 | 14 | 0.730 |
Why?
| Trimethoprim | 3 | 2016 | 11 | 0.720 |
Why?
| Drug Delivery Systems | 2 | 2019 | 5 | 0.710 |
Why?
| Rosuvastatin Calcium | 1 | 2020 | 5 | 0.710 |
Why?
| Baclofen | 2 | 2017 | 9 | 0.710 |
Why?
| Nicotinamide Phosphoribosyltransferase | 5 | 2018 | 8 | 0.700 |
Why?
| Maternal Exposure | 3 | 2017 | 3 | 0.700 |
Why?
| Umbilical Cord | 1 | 2019 | 1 | 0.700 |
Why?
| Cytokines | 5 | 2018 | 48 | 0.690 |
Why?
| Proteomics | 8 | 2024 | 24 | 0.670 |
Why?
| Drug Administration Schedule | 3 | 2018 | 35 | 0.660 |
Why?
| Codeine | 6 | 2014 | 15 | 0.660 |
Why?
| Opioid-Related Disorders | 3 | 2015 | 15 | 0.660 |
Why?
| Abnormalities, Drug-Induced | 3 | 2008 | 8 | 0.660 |
Why?
| Biological Transport | 6 | 2022 | 19 | 0.630 |
Why?
| Tissue Distribution | 4 | 2015 | 11 | 0.630 |
Why?
| Breast Feeding | 7 | 2011 | 25 | 0.620 |
Why?
| Research Design | 4 | 2019 | 63 | 0.610 |
Why?
| Placenta | 4 | 2017 | 21 | 0.610 |
Why?
| DNA Methylation | 2 | 2016 | 115 | 0.610 |
Why?
| Common Cold | 2 | 2015 | 2 | 0.610 |
Why?
| Nonprescription Drugs | 2 | 2015 | 2 | 0.610 |
Why?
| Cough | 2 | 2015 | 7 | 0.600 |
Why?
| DNA Copy Number Variations | 3 | 2020 | 37 | 0.600 |
Why?
| Central Nervous System Stimulants | 4 | 2016 | 11 | 0.600 |
Why?
| Antitussive Agents | 8 | 2015 | 13 | 0.600 |
Why?
| Prenatal Exposure Delayed Effects | 2 | 2015 | 9 | 0.590 |
Why?
| Brain | 3 | 2007 | 80 | 0.590 |
Why?
| Receptors, Cytoplasmic and Nuclear | 3 | 2007 | 4 | 0.580 |
Why?
| Aged | 10 | 2021 | 378 | 0.580 |
Why?
| Smoking | 2 | 2017 | 22 | 0.580 |
Why?
| Genetics, Population | 2 | 2016 | 11 | 0.570 |
Why?
| Asthma | 7 | 2015 | 157 | 0.570 |
Why?
| Gene Duplication | 3 | 2010 | 11 | 0.560 |
Why?
| Gestational Age | 12 | 2017 | 62 | 0.560 |
Why?
| Knowledge Bases | 1 | 2016 | 7 | 0.550 |
Why?
| Mice | 18 | 2024 | 348 | 0.550 |
Why?
| Sequence Analysis, DNA | 7 | 2022 | 115 | 0.550 |
Why?
| Metronidazole | 3 | 2024 | 16 | 0.540 |
Why?
| Intestine, Small | 1 | 2016 | 15 | 0.540 |
Why?
| Cytosine | 1 | 2016 | 5 | 0.540 |
Why?
| Tetrahydrofolates | 2 | 2014 | 3 | 0.540 |
Why?
| Crohn Disease | 1 | 2016 | 25 | 0.530 |
Why?
| Gene Expression Profiling | 9 | 2016 | 126 | 0.530 |
Why?
| Oxygenases | 3 | 2017 | 5 | 0.520 |
Why?
| Minor Histocompatibility Antigens | 4 | 2020 | 12 | 0.520 |
Why?
| DNA | 6 | 2013 | 41 | 0.520 |
Why?
| Opiate Substitution Treatment | 1 | 2015 | 2 | 0.520 |
Why?
| Neonatal Abstinence Syndrome | 1 | 2015 | 3 | 0.520 |
Why?
| Molecular Sequence Data | 11 | 2015 | 71 | 0.510 |
Why?
| Valproic Acid | 2 | 2013 | 2 | 0.500 |
Why?
| Absorption | 3 | 2014 | 7 | 0.500 |
Why?
| Health Care Costs | 2 | 2019 | 33 | 0.490 |
Why?
| Cotinine | 2 | 2017 | 4 | 0.470 |
Why?
| Statistics as Topic | 3 | 2016 | 18 | 0.460 |
Why?
| Arylsulfotransferase | 2 | 2011 | 8 | 0.460 |
Why?
| Aminoimidazole Carboxamide | 1 | 2013 | 1 | 0.450 |
Why?
| Erythroblasts | 1 | 2013 | 1 | 0.450 |
Why?
| Ribonucleotides | 1 | 2013 | 1 | 0.450 |
Why?
| Anti-Allergic Agents | 1 | 2013 | 6 | 0.440 |
Why?
| Rhinitis, Allergic, Perennial | 1 | 2013 | 10 | 0.440 |
Why?
| Caffeine | 7 | 2006 | 13 | 0.440 |
Why?
| Histamine | 1 | 2013 | 13 | 0.440 |
Why?
| Steroid 16-alpha-Hydroxylase | 3 | 2001 | 6 | 0.430 |
Why?
| Maternal Behavior | 1 | 2012 | 3 | 0.430 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 2 | 2010 | 39 | 0.430 |
Why?
| Phenytoin | 5 | 2012 | 9 | 0.430 |
Why?
| Treatment Outcome | 6 | 2023 | 622 | 0.430 |
Why?
| Cholesterol, LDL | 1 | 2012 | 7 | 0.420 |
Why?
| Cisapride | 2 | 2003 | 2 | 0.420 |
Why?
| Morphine | 4 | 2018 | 11 | 0.420 |
Why?
| Antirheumatic Agents | 4 | 2014 | 12 | 0.420 |
Why?
| Metabolic Networks and Pathways | 4 | 2013 | 10 | 0.420 |
Why?
| Dyslipidemias | 1 | 2012 | 15 | 0.420 |
Why?
| Hydroxylation | 5 | 2016 | 12 | 0.420 |
Why?
| Genetic Predisposition to Disease | 7 | 2017 | 231 | 0.420 |
Why?
| Area Under Curve | 8 | 2019 | 35 | 0.410 |
Why?
| Kidney | 3 | 2024 | 94 | 0.410 |
Why?
| Gene Expression | 7 | 2015 | 67 | 0.400 |
Why?
| Proton Pump Inhibitors | 2 | 2024 | 18 | 0.390 |
Why?
| Base Sequence | 8 | 2015 | 81 | 0.390 |
Why?
| Body Weight | 3 | 2022 | 52 | 0.390 |
Why?
| Carboxylic Acids | 1 | 2011 | 1 | 0.390 |
Why?
| Models, Genetic | 3 | 2007 | 33 | 0.390 |
Why?
| Metabolome | 1 | 2011 | 5 | 0.390 |
Why?
| Receptors, Opioid, mu | 2 | 2021 | 4 | 0.390 |
Why?
| Infant, Premature | 4 | 2022 | 85 | 0.380 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2012 | 71 | 0.380 |
Why?
| Mass Spectrometry | 6 | 2011 | 18 | 0.380 |
Why?
| Isoenzymes | 5 | 2017 | 19 | 0.380 |
Why?
| Risk Assessment | 5 | 2015 | 137 | 0.370 |
Why?
| Hospitalization | 1 | 2012 | 210 | 0.370 |
Why?
| Propylamines | 2 | 2024 | 4 | 0.370 |
Why?
| United States | 8 | 2018 | 669 | 0.370 |
Why?
| Case-Control Studies | 7 | 2017 | 215 | 0.370 |
Why?
| Longitudinal Studies | 3 | 2022 | 119 | 0.360 |
Why?
| Obesity | 2 | 2022 | 125 | 0.360 |
Why?
| Microfluidic Analytical Techniques | 1 | 2010 | 3 | 0.360 |
Why?
| Gene Dosage | 1 | 2010 | 13 | 0.360 |
Why?
| Drug Evaluation | 1 | 2010 | 1 | 0.360 |
Why?
| Risk Factors | 6 | 2015 | 487 | 0.360 |
Why?
| Mixed Function Oxygenases | 5 | 2003 | 14 | 0.350 |
Why?
| Sulfates | 2 | 2019 | 6 | 0.350 |
Why?
| Tandem Repeat Sequences | 1 | 2010 | 7 | 0.350 |
Why?
| Cluster Analysis | 4 | 2011 | 43 | 0.350 |
Why?
| Intensive Care Units, Neonatal | 3 | 2018 | 38 | 0.350 |
Why?
| Administration, Oral | 6 | 2017 | 58 | 0.340 |
Why?
| Hepatocytes | 2 | 2024 | 8 | 0.340 |
Why?
| Drug Costs | 1 | 2009 | 3 | 0.340 |
Why?
| Cell Survival | 5 | 1993 | 20 | 0.330 |
Why?
| Cohort Studies | 7 | 2017 | 289 | 0.330 |
Why?
| Infant, Newborn, Diseases | 1 | 2009 | 30 | 0.330 |
Why?
| Enzymes | 2 | 2021 | 4 | 0.330 |
Why?
| Exons | 6 | 2013 | 34 | 0.330 |
Why?
| Carbon Dioxide | 1 | 2008 | 14 | 0.320 |
Why?
| Breath Tests | 1 | 2008 | 11 | 0.320 |
Why?
| Oxidoreductases, N-Demethylating | 5 | 2003 | 8 | 0.320 |
Why?
| Antibodies | 3 | 1997 | 15 | 0.310 |
Why?
| Transcriptome | 3 | 2018 | 59 | 0.310 |
Why?
| Enzyme Inhibitors | 6 | 2016 | 21 | 0.310 |
Why?
| Steroid Hydroxylases | 4 | 2007 | 10 | 0.310 |
Why?
| Sulfamethoxazole | 5 | 1991 | 5 | 0.310 |
Why?
| Predictive Value of Tests | 6 | 2017 | 99 | 0.310 |
Why?
| Prospective Studies | 8 | 2022 | 525 | 0.300 |
Why?
| Anti-Ulcer Agents | 3 | 2010 | 8 | 0.300 |
Why?
| Metabolomics | 2 | 2020 | 18 | 0.300 |
Why?
| Rats | 10 | 2024 | 106 | 0.300 |
Why?
| Binding Sites | 5 | 2015 | 26 | 0.300 |
Why?
| DNA Primers | 5 | 2015 | 30 | 0.300 |
Why?
| Testosterone | 4 | 2020 | 30 | 0.290 |
Why?
| Organic Cation Transporter 1 | 2 | 2018 | 4 | 0.290 |
Why?
| Nicotine | 2 | 2019 | 10 | 0.290 |
Why?
| Depressive Disorder, Major | 2 | 2023 | 14 | 0.290 |
Why?
| Analgesics, Non-Narcotic | 3 | 2018 | 8 | 0.280 |
Why?
| Dextrorphan | 5 | 2022 | 13 | 0.270 |
Why?
| Protein Isoforms | 3 | 2020 | 16 | 0.270 |
Why?
| Sulfonamides | 2 | 1997 | 10 | 0.270 |
Why?
| Midazolam | 6 | 2015 | 12 | 0.270 |
Why?
| Chromatography, Liquid | 5 | 2024 | 9 | 0.270 |
Why?
| Substrate Specificity | 5 | 2016 | 16 | 0.270 |
Why?
| Computational Biology | 3 | 2013 | 43 | 0.270 |
Why?
| Anti-Infective Agents, Urinary | 2 | 2016 | 4 | 0.270 |
Why?
| Gene Expression Regulation | 2 | 2018 | 101 | 0.270 |
Why?
| Gene Rearrangement | 1 | 2006 | 7 | 0.270 |
Why?
| Muscle Relaxants, Central | 2 | 2017 | 7 | 0.270 |
Why?
| Cross-Sectional Studies | 3 | 2019 | 336 | 0.260 |
Why?
| Dibenzazepines | 1 | 2005 | 2 | 0.260 |
Why?
| Endoplasmic Reticulum | 2 | 1997 | 3 | 0.260 |
Why?
| RNA Splicing | 3 | 2015 | 14 | 0.260 |
Why?
| Glutathione | 6 | 2005 | 11 | 0.260 |
Why?
| Algorithms | 3 | 2010 | 105 | 0.260 |
Why?
| Recombinant Proteins | 4 | 2020 | 48 | 0.250 |
Why?
| Sulfotransferases | 2 | 2019 | 7 | 0.250 |
Why?
| Kinetics | 11 | 2008 | 31 | 0.250 |
Why?
| Tacrolimus | 2 | 2015 | 10 | 0.250 |
Why?
| Arylamine N-Acetyltransferase | 5 | 2005 | 18 | 0.240 |
Why?
| Genetic Association Studies | 4 | 2014 | 53 | 0.240 |
Why?
| Immunosuppressive Agents | 2 | 2015 | 31 | 0.240 |
Why?
| Methylation | 5 | 2016 | 11 | 0.240 |
Why?
| Sensitivity and Specificity | 5 | 2016 | 150 | 0.240 |
Why?
| Aldehyde Oxidase | 1 | 2024 | 1 | 0.240 |
Why?
| Indians, North American | 2 | 2001 | 9 | 0.240 |
Why?
| Species Specificity | 1 | 2024 | 10 | 0.240 |
Why?
| Congenital Abnormalities | 1 | 2004 | 17 | 0.240 |
Why?
| Fetal Diseases | 1 | 2004 | 9 | 0.240 |
Why?
| Specimen Handling | 1 | 2004 | 17 | 0.240 |
Why?
| Acetylcysteine | 5 | 2016 | 9 | 0.240 |
Why?
| Mice, Inbred C57BL | 5 | 2018 | 92 | 0.230 |
Why?
| Heterozygote | 1 | 2024 | 26 | 0.230 |
Why?
| Retrospective Studies | 5 | 2021 | 1296 | 0.230 |
Why?
| Antidepressive Agents | 2 | 2023 | 20 | 0.230 |
Why?
| Cytochrome P-450 CYP1A2 | 6 | 2006 | 12 | 0.230 |
Why?
| In Vitro Techniques | 7 | 2016 | 23 | 0.230 |
Why?
| Phenols | 2 | 2016 | 7 | 0.220 |
Why?
| Milk, Human | 4 | 2011 | 23 | 0.220 |
Why?
| RNA Interference | 1 | 2003 | 16 | 0.220 |
Why?
| Xanthine Oxidase | 6 | 2005 | 14 | 0.220 |
Why?
| Trichophyton | 2 | 2015 | 5 | 0.220 |
Why?
| Databases, Genetic | 3 | 2017 | 30 | 0.220 |
Why?
| Anesthesia | 1 | 2002 | 3 | 0.220 |
Why?
| Cytochrome P-450 CYP2B6 | 3 | 2023 | 11 | 0.220 |
Why?
| Naphthalenes | 2 | 1999 | 6 | 0.210 |
Why?
| Organic Anion Transporters | 2 | 2020 | 8 | 0.210 |
Why?
| Body Height | 1 | 2022 | 34 | 0.200 |
Why?
| Oximes | 1 | 2021 | 1 | 0.200 |
Why?
| Mitochondrial Proteins | 1 | 2021 | 7 | 0.200 |
Why?
| Pain | 2 | 2021 | 57 | 0.200 |
Why?
| NADPH-Ferrihemoprotein Reductase | 1 | 2021 | 2 | 0.200 |
Why?
| Hyperlipidemias | 2 | 2019 | 6 | 0.200 |
Why?
| Transcription, Genetic | 3 | 2013 | 44 | 0.200 |
Why?
| Body Surface Area | 1 | 2021 | 11 | 0.190 |
Why?
| High-Throughput Nucleotide Sequencing | 2 | 2022 | 99 | 0.190 |
Why?
| Maternal-Fetal Exchange | 3 | 2015 | 6 | 0.190 |
Why?
| Catechol O-Methyltransferase | 1 | 2021 | 5 | 0.190 |
Why?
| Terminology as Topic | 2 | 2017 | 14 | 0.190 |
Why?
| Body Mass Index | 1 | 2022 | 157 | 0.190 |
Why?
| Rare Diseases | 1 | 2022 | 48 | 0.190 |
Why?
| Prescription Drugs | 1 | 2021 | 4 | 0.190 |
Why?
| Warfarin | 4 | 2014 | 12 | 0.190 |
Why?
| Overweight | 1 | 2021 | 49 | 0.190 |
Why?
| Morpholines | 2 | 2018 | 2 | 0.190 |
Why?
| Autoantigens | 2 | 1998 | 5 | 0.190 |
Why?
| Adverse Drug Reaction Reporting Systems | 3 | 2010 | 13 | 0.190 |
Why?
| Sex Characteristics | 3 | 2017 | 12 | 0.180 |
Why?
| Tourette Syndrome | 1 | 2020 | 6 | 0.180 |
Why?
| Principal Component Analysis | 4 | 2016 | 14 | 0.180 |
Why?
| United States Food and Drug Administration | 2 | 2010 | 4 | 0.180 |
Why?
| Pilot Projects | 2 | 2019 | 120 | 0.180 |
Why?
| Aborted Fetus | 1 | 2020 | 1 | 0.180 |
Why?
| Stillbirth | 1 | 2020 | 1 | 0.180 |
Why?
| Androstadienes | 2 | 2013 | 2 | 0.180 |
Why?
| Netherlands | 1 | 2020 | 4 | 0.180 |
Why?
| Antineoplastic Agents | 2 | 2017 | 55 | 0.170 |
Why?
| Epitopes | 2 | 1998 | 20 | 0.170 |
Why?
| Dietary Supplements | 1 | 2019 | 25 | 0.170 |
Why?
| Prognosis | 2 | 2017 | 211 | 0.170 |
Why?
| Drug Overdose | 4 | 2015 | 5 | 0.170 |
Why?
| Aquaporin 2 | 1 | 2019 | 1 | 0.170 |
Why?
| Aquaporin 1 | 1 | 2019 | 2 | 0.170 |
Why?
| Organic Anion Transporters, Sodium-Independent | 2 | 2016 | 3 | 0.170 |
Why?
| Antifungal Agents | 2 | 2015 | 13 | 0.170 |
Why?
| Multidrug Resistance-Associated Proteins | 2 | 2016 | 5 | 0.170 |
Why?
| Reproducibility of Results | 6 | 2016 | 199 | 0.170 |
Why?
| Linear Models | 4 | 2017 | 56 | 0.170 |
Why?
| Time Factors | 7 | 2014 | 250 | 0.170 |
Why?
| Infant Formula | 2 | 2011 | 15 | 0.170 |
Why?
| Omeprazole | 4 | 2010 | 13 | 0.170 |
Why?
| Sequence Alignment | 2 | 2015 | 11 | 0.170 |
Why?
| Benzodiazepines | 2 | 2018 | 3 | 0.170 |
Why?
| Cytochrome P-450 CYP2A6 | 1 | 2019 | 4 | 0.170 |
Why?
| Molecular Targeted Therapy | 1 | 2019 | 10 | 0.160 |
Why?
| Analgesics | 2 | 2015 | 5 | 0.160 |
Why?
| Ambulatory Care Facilities | 1 | 2019 | 36 | 0.160 |
Why?
| Anti-Bacterial Agents | 2 | 2019 | 243 | 0.160 |
Why?
| NAD(P)H Dehydrogenase (Quinone) | 1 | 1998 | 5 | 0.160 |
Why?
| Urine Specimen Collection | 1 | 2018 | 1 | 0.160 |
Why?
| Ductus Arteriosus, Patent | 1 | 2018 | 4 | 0.160 |
Why?
| Glucuronides | 1 | 2018 | 3 | 0.160 |
Why?
| Protective Agents | 1 | 2018 | 2 | 0.160 |
Why?
| Research | 2 | 2018 | 13 | 0.160 |
Why?
| Androgens | 1 | 2018 | 8 | 0.160 |
Why?
| Renin-Angiotensin System | 1 | 2018 | 5 | 0.160 |
Why?
| Intracellular Space | 1 | 2018 | 1 | 0.160 |
Why?
| Adenosine Triphosphate | 1 | 2018 | 3 | 0.150 |
Why?
| Infant, Premature, Diseases | 1 | 2018 | 22 | 0.150 |
Why?
| Anticoagulants | 2 | 2014 | 20 | 0.150 |
Why?
| Fluorescent Dyes | 3 | 1993 | 14 | 0.150 |
Why?
| Gastroesophageal Reflux | 1 | 2018 | 41 | 0.150 |
Why?
| Sex Factors | 4 | 2024 | 68 | 0.150 |
Why?
| Antiemetics | 2 | 2017 | 4 | 0.150 |
Why?
| Adrenal Cortex Hormones | 2 | 2015 | 37 | 0.150 |
Why?
| Contraceptive Agents | 1 | 2018 | 13 | 0.150 |
Why?
| Enzyme Induction | 3 | 2012 | 4 | 0.150 |
Why?
| Telomere Shortening | 1 | 2017 | 1 | 0.150 |
Why?
| Patient Safety | 2 | 2015 | 20 | 0.150 |
Why?
| Intestinal Mucosa | 2 | 2017 | 41 | 0.150 |
Why?
| Sulfonylurea Receptors | 1 | 2017 | 7 | 0.150 |
Why?
| Hypersensitivity, Delayed | 1 | 1997 | 2 | 0.150 |
Why?
| Lung Diseases | 2 | 2016 | 23 | 0.150 |
Why?
| Proto-Oncogene Proteins | 2 | 2014 | 18 | 0.150 |
Why?
| Heat-Shock Proteins | 1 | 1997 | 7 | 0.150 |
Why?
| Reference Values | 4 | 2014 | 39 | 0.150 |
Why?
| Stevens-Johnson Syndrome | 1 | 2017 | 14 | 0.150 |
Why?
| Emergency Service, Hospital | 1 | 2019 | 130 | 0.150 |
Why?
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2017 | 1 | 0.150 |
Why?
| Aldehyde Dehydrogenase | 1 | 2017 | 3 | 0.150 |
Why?
| Alcohol Dehydrogenase | 1 | 2017 | 4 | 0.150 |
Why?
| Hypersensitivity | 1 | 1998 | 56 | 0.150 |
Why?
| Vomiting | 2 | 2017 | 23 | 0.140 |
Why?
| Genetic Heterogeneity | 1 | 2007 | 5 | 0.140 |
Why?
| Neonatal Screening | 1 | 2017 | 7 | 0.140 |
Why?
| Drug Evaluation, Preclinical | 2 | 2024 | 11 | 0.140 |
Why?
| Carboxylic Ester Hydrolases | 1 | 2016 | 2 | 0.140 |
Why?
| Carboxylesterase | 1 | 2016 | 2 | 0.140 |
Why?
| Oseltamivir | 1 | 2016 | 6 | 0.140 |
Why?
| Public Health | 1 | 2017 | 18 | 0.140 |
Why?
| Oxidation-Reduction | 3 | 2015 | 9 | 0.140 |
Why?
| Mutagenesis, Site-Directed | 3 | 2020 | 19 | 0.140 |
Why?
| Genome, Human | 2 | 2010 | 86 | 0.140 |
Why?
| Adolescent Development | 1 | 2016 | 4 | 0.140 |
Why?
| Computer Simulation | 1 | 2016 | 31 | 0.140 |
Why?
| Down-Regulation | 1 | 2016 | 15 | 0.140 |
Why?
| Microfilament Proteins | 1 | 2016 | 12 | 0.140 |
Why?
| Fluoresceins | 2 | 1993 | 2 | 0.130 |
Why?
| Lactones | 1 | 2016 | 3 | 0.130 |
Why?
| Bupropion | 1 | 2015 | 3 | 0.130 |
Why?
| Antigens | 1 | 1995 | 3 | 0.130 |
Why?
| Regression Analysis | 3 | 2011 | 52 | 0.130 |
Why?
| Pediatric Obesity | 1 | 2018 | 137 | 0.130 |
Why?
| Nasal Decongestants | 1 | 2015 | 1 | 0.130 |
Why?
| Antipyretics | 1 | 2015 | 1 | 0.130 |
Why?
| Histamine Antagonists | 1 | 2015 | 8 | 0.130 |
Why?
| Immunohistochemistry | 3 | 2015 | 48 | 0.130 |
Why?
| Vitamin K | 2 | 2005 | 5 | 0.130 |
Why?
| Beclomethasone | 1 | 2015 | 2 | 0.130 |
Why?
| Retinoid X Receptors | 2 | 2005 | 3 | 0.130 |
Why?
| RNA | 2 | 2005 | 14 | 0.130 |
Why?
| Sarcoma, Ewing | 1 | 2015 | 7 | 0.130 |
Why?
| Dexamethasone | 1 | 2015 | 29 | 0.130 |
Why?
| Canada | 4 | 2009 | 31 | 0.130 |
Why?
| Anti-Asthmatic Agents | 1 | 2015 | 11 | 0.130 |
Why?
| Fluoxetine | 1 | 2014 | 5 | 0.120 |
Why?
| Bone Neoplasms | 1 | 2015 | 23 | 0.120 |
Why?
| Genes, Reporter | 2 | 2005 | 13 | 0.120 |
Why?
| Cross-Over Studies | 4 | 2019 | 35 | 0.120 |
Why?
| Introns | 2 | 2005 | 7 | 0.120 |
Why?
| Biomarkers, Tumor | 1 | 2015 | 65 | 0.120 |
Why?
| Esterases | 2 | 1991 | 2 | 0.120 |
Why?
| Cystic Fibrosis | 2 | 2004 | 18 | 0.120 |
Why?
| Vitamin K Epoxide Reductases | 1 | 2014 | 2 | 0.120 |
Why?
| Cephalosporins | 2 | 1984 | 15 | 0.120 |
Why?
| Acute-Phase Proteins | 1 | 2014 | 1 | 0.120 |
Why?
| Lipocalins | 1 | 2014 | 1 | 0.120 |
Why?
| Membrane Glycoproteins | 1 | 2014 | 14 | 0.110 |
Why?
| Genetic Loci | 2 | 2013 | 40 | 0.110 |
Why?
| Cell Line | 3 | 2013 | 81 | 0.110 |
Why?
| Ethanolamines | 2 | 2005 | 4 | 0.110 |
Why?
| Vitamin D | 1 | 2013 | 22 | 0.110 |
Why?
| Tramadol | 2 | 2005 | 4 | 0.110 |
Why?
| K562 Cells | 1 | 2013 | 3 | 0.110 |
Why?
| Acute Kidney Injury | 1 | 2014 | 30 | 0.110 |
Why?
| Laser-Doppler Flowmetry | 1 | 2013 | 7 | 0.110 |
Why?
| Iontophoresis | 1 | 2013 | 7 | 0.110 |
Why?
| Epigenomics | 1 | 2013 | 27 | 0.110 |
Why?
| Methionine Sulfoximine | 1 | 1993 | 1 | 0.110 |
Why?
| Kidney Transplantation | 1 | 2014 | 115 | 0.110 |
Why?
| Rhinitis, Allergic | 1 | 2013 | 10 | 0.110 |
Why?
| Genotyping Techniques | 1 | 2013 | 22 | 0.110 |
Why?
| Autoantibodies | 1 | 1993 | 11 | 0.110 |
Why?
| Cytochrome P-450 CYP1B1 | 1 | 2012 | 1 | 0.110 |
Why?
| Cytochrome P-450 CYP1A1 | 1 | 2012 | 2 | 0.110 |
Why?
| Bronchodilator Agents | 1 | 2013 | 11 | 0.110 |
Why?
| Models, Animal | 1 | 2012 | 10 | 0.110 |
Why?
| Up-Regulation | 1 | 2012 | 25 | 0.110 |
Why?
| ROC Curve | 1 | 2012 | 22 | 0.110 |
Why?
| Diarrhea | 1 | 2012 | 18 | 0.110 |
Why?
| Soft Tissue Infections | 1 | 2012 | 12 | 0.110 |
Why?
| Inhibitory Concentration 50 | 2 | 2020 | 7 | 0.110 |
Why?
| Antibodies, Anti-Idiotypic | 1 | 1992 | 3 | 0.110 |
Why?
| Stereoisomerism | 3 | 2020 | 9 | 0.110 |
Why?
| Body Size | 1 | 2012 | 7 | 0.110 |
Why?
| Immunoglobulin G | 1 | 1992 | 34 | 0.110 |
Why?
| Genome-Wide Association Study | 4 | 2017 | 190 | 0.110 |
Why?
| Deferoxamine | 2 | 1989 | 3 | 0.100 |
Why?
| Cells, Cultured | 5 | 2011 | 84 | 0.100 |
Why?
| Ferredoxin-NADP Reductase | 1 | 2012 | 1 | 0.100 |
Why?
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2012 | 6 | 0.100 |
Why?
| Cloning, Molecular | 2 | 2005 | 8 | 0.100 |
Why?
| Cytochrome P-450 CYP2C9 | 4 | 2014 | 25 | 0.100 |
Why?
| Antimanic Agents | 1 | 2011 | 1 | 0.100 |
Why?
| Saliva | 1 | 2011 | 10 | 0.100 |
Why?
| Gene Deletion | 1 | 2011 | 13 | 0.100 |
Why?
| RNA 3' End Processing | 1 | 2011 | 1 | 0.100 |
Why?
| Blood | 1 | 2011 | 10 | 0.100 |
Why?
| Isoflavones | 1 | 2011 | 1 | 0.100 |
Why?
| Soybean Proteins | 1 | 2011 | 1 | 0.100 |
Why?
| Soy Foods | 1 | 2011 | 2 | 0.100 |
Why?
| Citalopram | 2 | 2023 | 14 | 0.100 |
Why?
| Antimetabolites, Antineoplastic | 1 | 2011 | 26 | 0.100 |
Why?
| Lactic Acid | 1 | 2011 | 3 | 0.100 |
Why?
| Clozapine | 2 | 2003 | 3 | 0.100 |
Why?
| Aged, 80 and over | 3 | 2018 | 151 | 0.100 |
Why?
| Antioxidants | 1 | 2011 | 5 | 0.100 |
Why?
| Transcription Factors | 2 | 2015 | 52 | 0.100 |
Why?
| Killer Cells, Natural | 1 | 1991 | 13 | 0.090 |
Why?
| Government Regulation | 1 | 2010 | 1 | 0.090 |
Why?
| Betaine-Homocysteine S-Methyltransferase | 1 | 2010 | 2 | 0.090 |
Why?
| Toll-Like Receptors | 1 | 2010 | 14 | 0.090 |
Why?
| Chromatography, Reverse-Phase | 1 | 2010 | 1 | 0.090 |
Why?
| Drug Administration Routes | 1 | 2010 | 3 | 0.090 |
Why?
| Oligonucleotide Array Sequence Analysis | 4 | 2011 | 47 | 0.090 |
Why?
| China | 2 | 2001 | 9 | 0.090 |
Why?
| Forecasting | 2 | 2022 | 22 | 0.090 |
Why?
| Disulfides | 1 | 2010 | 2 | 0.090 |
Why?
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2010 | 6 | 0.090 |
Why?
| Expectorants | 1 | 2010 | 2 | 0.090 |
Why?
| Models, Statistical | 2 | 2014 | 29 | 0.090 |
Why?
| Hybridization, Genetic | 1 | 2010 | 3 | 0.090 |
Why?
| Tinea | 1 | 2010 | 4 | 0.090 |
Why?
| Patient Selection | 1 | 2010 | 40 | 0.090 |
Why?
| Environmental Pollutants | 1 | 2009 | 1 | 0.090 |
Why?
| Benzhydryl Compounds | 1 | 2009 | 3 | 0.090 |
Why?
| Fetal Development | 1 | 2009 | 4 | 0.090 |
Why?
| Wnt Proteins | 1 | 2009 | 11 | 0.090 |
Why?
| HEK293 Cells | 2 | 2020 | 32 | 0.090 |
Why?
| National Health Programs | 1 | 2009 | 1 | 0.090 |
Why?
| Gastroschisis | 1 | 2009 | 23 | 0.090 |
Why?
| Severity of Illness Index | 1 | 2010 | 149 | 0.090 |
Why?
| Economics, Pharmaceutical | 1 | 2009 | 1 | 0.080 |
Why?
| Child Health Services | 1 | 2009 | 24 | 0.080 |
Why?
| Iron | 1 | 1989 | 14 | 0.080 |
Why?
| Drugs, Investigational | 1 | 2008 | 1 | 0.080 |
Why?
| Investigational New Drug Application | 1 | 2008 | 1 | 0.080 |
Why?
| Schizophrenia | 1 | 2008 | 3 | 0.080 |
Why?
| Carbon Isotopes | 1 | 2008 | 4 | 0.080 |
Why?
| Protein Binding | 2 | 2007 | 31 | 0.080 |
Why?
| Clinical Trials as Topic | 1 | 2008 | 45 | 0.080 |
Why?
| Lymphocytes | 1 | 1988 | 15 | 0.080 |
Why?
| Feasibility Studies | 1 | 2008 | 58 | 0.080 |
Why?
| Kidney Diseases | 1 | 2008 | 71 | 0.080 |
Why?
| Pyridines | 2 | 1988 | 4 | 0.080 |
Why?
| Adrenergic beta-Antagonists | 2 | 2004 | 6 | 0.080 |
Why?
| Hospitals, Pediatric | 1 | 2009 | 187 | 0.080 |
Why?
| Nausea | 2 | 2018 | 16 | 0.070 |
Why?
| Pedigree | 2 | 2022 | 59 | 0.070 |
Why?
| Transfection | 2 | 2004 | 22 | 0.070 |
Why?
| Amino Acid Sequence | 2 | 1998 | 32 | 0.070 |
Why?
| Healthy Volunteers | 2 | 2019 | 8 | 0.070 |
Why?
| Dealkylation | 1 | 2007 | 2 | 0.070 |
Why?
| Buserelin | 1 | 1986 | 1 | 0.070 |
Why?
| Puberty, Precocious | 1 | 1986 | 2 | 0.070 |
Why?
| Mice, SCID | 3 | 1996 | 13 | 0.070 |
Why?
| Hydrogen-Ion Concentration | 2 | 2020 | 19 | 0.070 |
Why?
| Paroxetine | 1 | 2006 | 3 | 0.070 |
Why?
| Antidepressive Agents, Second-Generation | 1 | 2006 | 4 | 0.070 |
Why?
| Obsessive-Compulsive Disorder | 1 | 2006 | 6 | 0.070 |
Why?
| Genetic Markers | 3 | 2015 | 22 | 0.070 |
Why?
| Cytochrome P-450 Enzyme Inhibitors | 3 | 2006 | 6 | 0.070 |
Why?
| Open Reading Frames | 1 | 2006 | 3 | 0.070 |
Why?
| Anti-Inflammatory Agents | 1 | 2006 | 11 | 0.070 |
Why?
| Antimetabolites | 2 | 2018 | 4 | 0.070 |
Why?
| Theophylline | 1 | 1986 | 2 | 0.070 |
Why?
| Ethinyl Estradiol | 1 | 2005 | 2 | 0.070 |
Why?
| Norgestrel | 1 | 2005 | 2 | 0.070 |
Why?
| Contraceptives, Oral | 1 | 2005 | 3 | 0.070 |
Why?
| Heart Defects, Congenital | 1 | 2007 | 81 | 0.070 |
Why?
| Dogs | 3 | 2018 | 17 | 0.070 |
Why?
| Xenobiotics | 1 | 2005 | 3 | 0.070 |
Why?
| Hepatocyte Nuclear Factor 4 | 1 | 2005 | 3 | 0.070 |
Why?
| Follow-Up Studies | 2 | 2018 | 304 | 0.070 |
Why?
| COS Cells | 2 | 2002 | 19 | 0.070 |
Why?
| Haptens | 2 | 1996 | 3 | 0.070 |
Why?
| Cross Reactions | 2 | 1997 | 8 | 0.060 |
Why?
| HLA Antigens | 2 | 2011 | 13 | 0.060 |
Why?
| Half-Life | 4 | 2014 | 12 | 0.060 |
Why?
| Dehydroepiandrosterone | 1 | 2005 | 2 | 0.060 |
Why?
| Catalysis | 1 | 2005 | 4 | 0.060 |
Why?
| Rats, Sprague-Dawley | 2 | 1997 | 50 | 0.060 |
Why?
| Doxylamine | 2 | 1988 | 2 | 0.060 |
Why?
| Pyridoxine | 2 | 1988 | 2 | 0.060 |
Why?
| Luciferases | 1 | 2005 | 6 | 0.060 |
Why?
| Metoprolol | 1 | 2004 | 4 | 0.060 |
Why?
| Drug Combinations | 5 | 2005 | 19 | 0.060 |
Why?
| Models, Molecular | 2 | 2007 | 14 | 0.060 |
Why?
| Cytochrome P-450 CYP2E1 | 2 | 1996 | 4 | 0.060 |
Why?
| Dimerization | 1 | 2004 | 4 | 0.060 |
Why?
| Plasmids | 1 | 2004 | 5 | 0.060 |
Why?
| Drug Eruptions | 1 | 2004 | 3 | 0.060 |
Why?
| Enzyme Activation | 2 | 2018 | 12 | 0.060 |
Why?
| Administration, Inhalation | 2 | 2015 | 19 | 0.060 |
Why?
| Hypertension | 1 | 2004 | 66 | 0.060 |
Why?
| Phenyl Ethers | 1 | 2024 | 1 | 0.060 |
Why?
| Legislation, Drug | 1 | 1983 | 1 | 0.060 |
Why?
| Myocardium | 1 | 2003 | 8 | 0.060 |
Why?
| Drug Therapy | 1 | 2003 | 7 | 0.060 |
Why?
| Information Theory | 1 | 2003 | 1 | 0.060 |
Why?
| Serotonin | 1 | 2023 | 4 | 0.060 |
Why?
| Serotonin Plasma Membrane Transport Proteins | 1 | 2023 | 7 | 0.060 |
Why?
| Technology, Pharmaceutical | 1 | 2003 | 1 | 0.060 |
Why?
| Signal Transduction | 2 | 2017 | 132 | 0.060 |
Why?
| Databases, Protein | 1 | 2003 | 2 | 0.060 |
Why?
| Animals, Newborn | 2 | 2015 | 32 | 0.060 |
Why?
| LLC-PK1 Cells | 1 | 2003 | 1 | 0.060 |
Why?
| Amino Acid Substitution | 1 | 2003 | 12 | 0.060 |
Why?
| Swine | 1 | 2003 | 6 | 0.060 |
Why?
| Models, Theoretical | 1 | 2003 | 13 | 0.050 |
Why?
| Acetyltransferases | 2 | 2003 | 4 | 0.050 |
Why?
| Mutation, Missense | 1 | 2003 | 28 | 0.050 |
Why?
| Infusions, Intravenous | 1 | 2003 | 26 | 0.050 |
Why?
| DNA, Complementary | 1 | 2002 | 9 | 0.050 |
Why?
| Epoxide Hydrolases | 2 | 2005 | 6 | 0.050 |
Why?
| Herpesvirus 4, Human | 2 | 1993 | 5 | 0.050 |
Why?
| Lymphoma | 2 | 1993 | 9 | 0.050 |
Why?
| Anti-Anxiety Agents | 2 | 2000 | 5 | 0.050 |
Why?
| Debrisoquin | 1 | 2002 | 5 | 0.050 |
Why?
| Imines | 2 | 1993 | 3 | 0.050 |
Why?
| Benzoquinones | 2 | 1993 | 3 | 0.050 |
Why?
| Genome | 1 | 2022 | 32 | 0.050 |
Why?
| Human Genome Project | 1 | 2002 | 3 | 0.050 |
Why?
| Oxidoreductases | 1 | 2021 | 9 | 0.050 |
Why?
| Genetic Therapy | 1 | 2002 | 7 | 0.050 |
Why?
| Genetics, Medical | 1 | 2002 | 5 | 0.050 |
Why?
| Menstrual Cycle | 2 | 1998 | 6 | 0.050 |
Why?
| Hepatobiliary Elimination | 1 | 2021 | 2 | 0.050 |
Why?
| Datasets as Topic | 1 | 2021 | 7 | 0.050 |
Why?
| Organ Size | 1 | 2021 | 14 | 0.050 |
Why?
| Methyltransferases | 1 | 2001 | 9 | 0.050 |
Why?
| Intensive Care Units, Pediatric | 1 | 2001 | 11 | 0.050 |
Why?
| Fluorescence | 2 | 1991 | 8 | 0.050 |
Why?
| Tomography, X-Ray Computed | 1 | 2021 | 117 | 0.050 |
Why?
| Ceftazidime | 3 | 1985 | 4 | 0.050 |
Why?
| Magnetic Resonance Imaging | 1 | 2021 | 122 | 0.040 |
Why?
| Iatrogenic Disease | 1 | 2000 | 7 | 0.040 |
Why?
| Fluticasone | 2 | 2013 | 2 | 0.040 |
Why?
| Polymorphism, Restriction Fragment Length | 1 | 1999 | 9 | 0.040 |
Why?
| Phenobarbital | 2 | 1993 | 2 | 0.040 |
Why?
| Marketing of Health Services | 1 | 2019 | 3 | 0.040 |
Why?
| Drug Labeling | 1 | 2019 | 4 | 0.040 |
Why?
| Immunoblotting | 2 | 1998 | 11 | 0.040 |
Why?
| Sertraline | 1 | 2019 | 11 | 0.040 |
Why?
| Kidney Tubules, Proximal | 1 | 2019 | 1 | 0.040 |
Why?
| Kidney Tubules, Collecting | 1 | 2019 | 3 | 0.040 |
Why?
| Glucuronates | 1 | 1999 | 2 | 0.040 |
Why?
| Inappropriate Prescribing | 1 | 2019 | 27 | 0.040 |
Why?
| Hospital Costs | 1 | 2019 | 29 | 0.040 |
Why?
| Fluvoxamine | 1 | 1998 | 2 | 0.040 |
Why?
| Madin Darby Canine Kidney Cells | 1 | 2018 | 1 | 0.040 |
Why?
| Zidovudine | 1 | 2018 | 2 | 0.040 |
Why?
| Pirenzepine | 1 | 1998 | 1 | 0.040 |
Why?
| Thromboxane-A Synthase | 1 | 1998 | 2 | 0.040 |
Why?
| Intramolecular Oxidoreductases | 1 | 1998 | 2 | 0.040 |
Why?
| Epitope Mapping | 1 | 1998 | 7 | 0.040 |
Why?
| Neutrophils | 1 | 1998 | 11 | 0.040 |
Why?
| Oxidative Stress | 1 | 2018 | 17 | 0.040 |
Why?
| Peptidyl-Dipeptidase A | 1 | 2018 | 3 | 0.040 |
Why?
| Factor V | 1 | 2018 | 3 | 0.040 |
Why?
| Mice, Knockout | 1 | 2018 | 59 | 0.040 |
Why?
| Homeostasis | 1 | 2018 | 8 | 0.040 |
Why?
| Models, Immunological | 1 | 1998 | 1 | 0.040 |
Why?
| Gene Silencing | 1 | 2018 | 13 | 0.040 |
Why?
| Necrosis | 1 | 2017 | 2 | 0.040 |
Why?
| Cell Proliferation | 1 | 2018 | 58 | 0.040 |
Why?
| Epilepsy | 1 | 1998 | 14 | 0.040 |
Why?
| Isomerases | 1 | 1997 | 1 | 0.040 |
Why?
| Precipitin Tests | 1 | 1997 | 1 | 0.040 |
Why?
| Protein Disulfide-Isomerases | 1 | 1997 | 1 | 0.040 |
Why?
| Molecular Chaperones | 1 | 1997 | 7 | 0.040 |
Why?
| Quetiapine Fumarate | 1 | 2017 | 1 | 0.040 |
Why?
| Cytochrome P-450 CYP2C9 Inducers | 1 | 2017 | 1 | 0.040 |
Why?
| Oxycodone | 1 | 2017 | 4 | 0.040 |
Why?
| Ethanol | 1 | 2017 | 7 | 0.040 |
Why?
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2017 | 4 | 0.040 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 41 | 0.040 |
Why?
| Incidence | 1 | 2017 | 133 | 0.040 |
Why?
| Carrier Proteins | 1 | 1997 | 35 | 0.040 |
Why?
| Citric Acid Cycle | 1 | 2017 | 1 | 0.040 |
Why?
| Fatty Acids, Unsaturated | 1 | 2017 | 1 | 0.040 |
Why?
| NAD | 1 | 2017 | 2 | 0.040 |
Why?
| Delivery of Health Care, Integrated | 1 | 2017 | 7 | 0.040 |
Why?
| Databases, Factual | 1 | 2017 | 108 | 0.040 |
Why?
| Embryonic Stem Cells | 1 | 2017 | 11 | 0.040 |
Why?
| Gene Amplification | 1 | 2007 | 4 | 0.040 |
Why?
| Triglycerides | 1 | 2017 | 22 | 0.040 |
Why?
| Cost-Benefit Analysis | 1 | 2017 | 25 | 0.040 |
Why?
| Genomic Structural Variation | 1 | 2017 | 3 | 0.040 |
Why?
| Tumor Cells, Cultured | 2 | 1996 | 25 | 0.040 |
Why?
| Genetic Research | 1 | 2017 | 5 | 0.040 |
Why?
| Exome | 1 | 2017 | 36 | 0.040 |
Why?
| Intestines | 1 | 2017 | 29 | 0.040 |
Why?
| Neoplasm Proteins | 1 | 2016 | 31 | 0.030 |
Why?
| Demography | 1 | 2016 | 8 | 0.030 |
Why?
| Tyrphostins | 1 | 1996 | 1 | 0.030 |
Why?
| Nitriles | 1 | 1996 | 3 | 0.030 |
Why?
| Protein-Tyrosine Kinases | 1 | 1996 | 7 | 0.030 |
Why?
| Sequence Homology, Amino Acid | 1 | 1996 | 6 | 0.030 |
Why?
| Binding Sites, Antibody | 1 | 1996 | 4 | 0.030 |
Why?
| Consensus Sequence | 1 | 1996 | 3 | 0.030 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 1996 | 9 | 0.030 |
Why?
| Gene Library | 1 | 1996 | 5 | 0.030 |
Why?
| Isomerism | 1 | 2016 | 2 | 0.030 |
Why?
| Blotting, Western | 1 | 1996 | 17 | 0.030 |
Why?
| Peptide Fragments | 1 | 1996 | 12 | 0.030 |
Why?
| Consumer Product Safety | 1 | 1995 | 1 | 0.030 |
Why?
| Prilocaine | 1 | 1995 | 1 | 0.030 |
Why?
| Lidocaine | 1 | 1995 | 6 | 0.030 |
Why?
| Antigen-Antibody Reactions | 1 | 1995 | 1 | 0.030 |
Why?
| Antibody Specificity | 1 | 1995 | 8 | 0.030 |
Why?
| High-Throughput Screening Assays | 1 | 2015 | 4 | 0.030 |
Why?
| CCAAT-Enhancer-Binding Protein-delta | 1 | 2015 | 1 | 0.030 |
Why?
| Organ Transplantation | 1 | 2015 | 6 | 0.030 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1996 | 52 | 0.030 |
Why?
| Tacrolimus Binding Proteins | 1 | 2015 | 6 | 0.030 |
Why?
| Microbial Sensitivity Tests | 1 | 2015 | 33 | 0.030 |
Why?
| Diarrhea, Infantile | 1 | 1995 | 2 | 0.030 |
Why?
| Biomedical Research | 1 | 2015 | 27 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2015 | 19 | 0.030 |
Why?
| Counseling | 1 | 1995 | 28 | 0.030 |
Why?
| Disease Management | 1 | 2015 | 34 | 0.030 |
Why?
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2014 | 1 | 0.030 |
Why?
| Survival Rate | 1 | 2015 | 83 | 0.030 |
Why?
| Disease Progression | 1 | 2015 | 111 | 0.030 |
Why?
| Neoplasms | 1 | 2017 | 128 | 0.030 |
Why?
| CpG Islands | 1 | 2014 | 53 | 0.030 |
Why?
| Clotrimazole | 1 | 2014 | 3 | 0.030 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 50 | 0.030 |
Why?
| Gene Ontology | 1 | 2014 | 6 | 0.030 |
Why?
| Anti-Infective Agents, Local | 1 | 2014 | 8 | 0.030 |
Why?
| Leukocytes, Mononuclear | 2 | 1991 | 16 | 0.030 |
Why?
| International Normalized Ratio | 1 | 2014 | 4 | 0.030 |
Why?
| Receptors, Virus | 1 | 2014 | 2 | 0.030 |
Why?
| Risk | 1 | 2014 | 41 | 0.030 |
Why?
| Immunocompetence | 1 | 1993 | 1 | 0.030 |
Why?
| Tumor Virus Infections | 1 | 1993 | 1 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2014 | 71 | 0.030 |
Why?
| Hemorrhage | 1 | 2014 | 19 | 0.030 |
Why?
| T-Lymphocytes | 1 | 1993 | 31 | 0.030 |
Why?
| Hep G2 Cells | 1 | 2013 | 6 | 0.030 |
Why?
| Cardiac Surgical Procedures | 1 | 2014 | 30 | 0.030 |
Why?
| Linkage Disequilibrium | 1 | 2013 | 34 | 0.030 |
Why?
| Glutathione Reductase | 2 | 1991 | 2 | 0.030 |
Why?
| Transition Temperature | 1 | 2013 | 2 | 0.030 |
Why?
| Joints | 1 | 2013 | 3 | 0.030 |
Why?
| Buthionine Sulfoximine | 1 | 1993 | 2 | 0.030 |
Why?
| Cell Adhesion | 1 | 1993 | 9 | 0.030 |
Why?
| Drug Therapy, Combination | 1 | 2013 | 35 | 0.030 |
Why?
| Epilepsy, Tonic-Clonic | 1 | 1993 | 1 | 0.030 |
Why?
| Epilepsies, Partial | 1 | 1993 | 5 | 0.030 |
Why?
| Antibodies, Monoclonal | 1 | 2013 | 23 | 0.030 |
Why?
| Postoperative Complications | 1 | 2014 | 184 | 0.030 |
Why?
| Deuterium | 1 | 2011 | 1 | 0.030 |
Why?
| Isotope Labeling | 1 | 2011 | 1 | 0.030 |
Why?
| Phenethylamines | 1 | 2011 | 4 | 0.030 |
Why?
| Ions | 1 | 2011 | 2 | 0.030 |
Why?
| Polyadenylation | 1 | 2011 | 2 | 0.020 |
Why?
| Phytoestrogens | 1 | 2011 | 2 | 0.020 |
Why?
| Cell Differentiation | 1 | 2011 | 59 | 0.020 |
Why?
| Odds Ratio | 1 | 2011 | 51 | 0.020 |
Why?
| Methylamines | 1 | 2011 | 2 | 0.020 |
Why?
| Metabolism, Inborn Errors | 1 | 2011 | 6 | 0.020 |
Why?
| Digoxin | 1 | 1991 | 1 | 0.020 |
Why?
| Surveys and Questionnaires | 1 | 2013 | 274 | 0.020 |
Why?
| Cytotoxicity, Immunologic | 1 | 1991 | 1 | 0.020 |
Why?
| Cell Membrane | 1 | 1991 | 8 | 0.020 |
Why?
| Excitatory Amino Acid Antagonists | 2 | 2002 | 6 | 0.020 |
Why?
| Toll-Like Receptor 2 | 1 | 2010 | 4 | 0.020 |
Why?
| Morphogenesis | 1 | 2010 | 9 | 0.020 |
Why?
| Calcium | 1 | 1990 | 41 | 0.020 |
Why?
| Toll-Like Receptor 4 | 1 | 2010 | 11 | 0.020 |
Why?
| Systems Biology | 1 | 2010 | 4 | 0.020 |
Why?
| Emigration and Immigration | 1 | 2010 | 2 | 0.020 |
Why?
| Geography | 1 | 2010 | 2 | 0.020 |
Why?
| DNA, Ribosomal Spacer | 1 | 2010 | 3 | 0.020 |
Why?
| Evolution, Molecular | 1 | 2010 | 6 | 0.020 |
Why?
| Australia | 1 | 2010 | 10 | 0.020 |
Why?
| DNA, Fungal | 1 | 2010 | 6 | 0.020 |
Why?
| Virulence | 1 | 2010 | 7 | 0.020 |
Why?
| Asia | 1 | 2010 | 10 | 0.020 |
Why?
| Dithionitrobenzoic Acid | 1 | 1989 | 1 | 0.020 |
Why?
| Microchemistry | 1 | 1989 | 1 | 0.020 |
Why?
| Nitrobenzoates | 1 | 1989 | 1 | 0.020 |
Why?
| Vital Capacity | 1 | 2009 | 6 | 0.020 |
Why?
| Europe | 1 | 2010 | 37 | 0.020 |
Why?
| Forced Expiratory Volume | 1 | 2009 | 10 | 0.020 |
Why?
| North America | 1 | 2010 | 44 | 0.020 |
Why?
| Pulmonary Surfactants | 1 | 2009 | 2 | 0.020 |
Why?
| Hypnotics and Sedatives | 2 | 2000 | 6 | 0.020 |
Why?
| Delayed-Action Preparations | 2 | 1987 | 3 | 0.020 |
Why?
| Hearing Loss | 1 | 2009 | 4 | 0.020 |
Why?
| Antibiotics, Antineoplastic | 1 | 2009 | 7 | 0.020 |
Why?
| Anthracyclines | 1 | 2009 | 6 | 0.020 |
Why?
| Cisplatin | 1 | 2009 | 10 | 0.020 |
Why?
| Program Development | 1 | 2009 | 12 | 0.020 |
Why?
| Heart Diseases | 1 | 2009 | 19 | 0.020 |
Why?
| Spectrometry, Fluorescence | 1 | 1989 | 1 | 0.020 |
Why?
| Monocytes | 1 | 1989 | 9 | 0.020 |
Why?
| Mutation | 1 | 2010 | 212 | 0.020 |
Why?
| Epidemiologic Methods | 1 | 1988 | 2 | 0.020 |
Why?
| Meta-Analysis as Topic | 1 | 1988 | 14 | 0.020 |
Why?
| Apnea | 1 | 2008 | 5 | 0.020 |
Why?
| Double-Blind Method | 1 | 2008 | 44 | 0.020 |
Why?
| Tetrazolium Salts | 1 | 1988 | 1 | 0.020 |
Why?
| Thiazoles | 1 | 1988 | 1 | 0.020 |
Why?
| NADP | 1 | 1988 | 2 | 0.020 |
Why?
| Glutathione Transferase | 1 | 1988 | 2 | 0.020 |
Why?
| Dicyclomine | 2 | 1988 | 2 | 0.020 |
Why?
| Structure-Activity Relationship | 2 | 1999 | 7 | 0.020 |
Why?
| Practice Guidelines as Topic | 1 | 2008 | 108 | 0.020 |
Why?
| Crystallography, X-Ray | 1 | 2007 | 4 | 0.020 |
Why?
| Erythromycin | 1 | 2007 | 3 | 0.020 |
Why?
| Amino Acid Motifs | 1 | 2007 | 2 | 0.020 |
Why?
| Sequence Homology, Nucleic Acid | 1 | 2007 | 4 | 0.020 |
Why?
| Software | 1 | 2007 | 30 | 0.020 |
Why?
| Quinidine | 1 | 1987 | 1 | 0.020 |
Why?
| Fatal Outcome | 1 | 2007 | 7 | 0.020 |
Why?
| Radioimmunoassay | 1 | 1986 | 3 | 0.020 |
Why?
| Administration, Intranasal | 1 | 1986 | 8 | 0.020 |
Why?
| Antibody Formation | 1 | 1986 | 4 | 0.020 |
Why?
| Injections, Subcutaneous | 1 | 1986 | 8 | 0.020 |
Why?
| Ketoconazole | 1 | 2006 | 1 | 0.020 |
Why?
| Mifepristone | 1 | 2006 | 2 | 0.020 |
Why?
| Psychometrics | 1 | 2006 | 30 | 0.020 |
Why?
| Fruit | 1 | 1986 | 10 | 0.020 |
Why?
| Therapeutic Equivalency | 1 | 2005 | 5 | 0.020 |
Why?
| Tobramycin | 1 | 1985 | 3 | 0.020 |
Why?
| Dosage Forms | 1 | 2005 | 1 | 0.020 |
Why?
| Transferases | 1 | 2005 | 1 | 0.020 |
Why?
| Gentamicins | 1 | 1985 | 5 | 0.020 |
Why?
| Infant, Low Birth Weight | 1 | 1985 | 14 | 0.020 |
Why?
| Sputum | 1 | 1984 | 2 | 0.020 |
Why?
| Injections, Intravenous | 1 | 1984 | 15 | 0.020 |
Why?
| Pseudomonas aeruginosa | 1 | 1984 | 7 | 0.020 |
Why?
| Pseudomonas Infections | 1 | 1984 | 7 | 0.020 |
Why?
| Blood Pressure | 1 | 2004 | 67 | 0.020 |
Why?
| Glucagon | 1 | 1984 | 3 | 0.010 |
Why?
| Public Opinion | 1 | 1983 | 2 | 0.010 |
Why?
| Drug Industry | 1 | 1983 | 2 | 0.010 |
Why?
| Phosphodiesterase Inhibitors | 1 | 2003 | 4 | 0.010 |
Why?
| Molecular Structure | 1 | 2003 | 4 | 0.010 |
Why?
| Microsomes | 1 | 2003 | 5 | 0.010 |
Why?
| Vitamins | 1 | 2003 | 11 | 0.010 |
Why?
| Computer Graphics | 1 | 2003 | 1 | 0.010 |
Why?
| Computer Systems | 1 | 2003 | 1 | 0.010 |
Why?
| Programming Languages | 1 | 2003 | 1 | 0.010 |
Why?
| E-Box Elements | 1 | 2003 | 1 | 0.010 |
Why?
| RNA Splice Sites | 1 | 2003 | 2 | 0.010 |
Why?
| Response Elements | 1 | 2003 | 2 | 0.010 |
Why?
| User-Computer Interface | 1 | 2003 | 11 | 0.010 |
Why?
| Transplantation, Heterologous | 2 | 1993 | 6 | 0.010 |
Why?
| Least-Squares Analysis | 1 | 2002 | 2 | 0.010 |
Why?
| Birth Weight | 2 | 1995 | 28 | 0.010 |
Why?
| Protein Conformation | 1 | 1999 | 5 | 0.010 |
Why?
| Embryonic and Fetal Development | 1 | 1999 | 6 | 0.010 |
Why?
| Volunteers | 1 | 1999 | 2 | 0.010 |
Why?
| Follicular Phase | 1 | 1998 | 3 | 0.010 |
Why?
| Luteal Phase | 1 | 1998 | 3 | 0.010 |
Why?
| Analysis of Variance | 1 | 1998 | 22 | 0.010 |
Why?
| Cytochrome P-450 CYP1A2 Inhibitors | 1 | 1998 | 1 | 0.010 |
Why?
| Evaluation Studies as Topic | 1 | 1998 | 8 | 0.010 |
Why?
| Hypochlorous Acid | 1 | 1998 | 1 | 0.010 |
Why?
| Immune Sera | 1 | 1998 | 1 | 0.010 |
Why?
| Peroxidase | 1 | 1998 | 1 | 0.010 |
Why?
| Rats, Inbred Lew | 1 | 1998 | 1 | 0.010 |
Why?
| Rabbits | 1 | 1998 | 5 | 0.010 |
Why?
| Bone Marrow | 1 | 1998 | 6 | 0.010 |
Why?
| Free Radical Scavengers | 1 | 1998 | 1 | 0.010 |
Why?
| Restriction Mapping | 1 | 1997 | 6 | 0.010 |
Why?
| Janus Kinase 2 | 1 | 1996 | 8 | 0.010 |
Why?
| Neoplasm Transplantation | 1 | 1996 | 8 | 0.010 |
Why?
| Cell Division | 1 | 1996 | 12 | 0.010 |
Why?
| B-Lymphocytes | 1 | 1996 | 24 | 0.010 |
Why?
| Chi-Square Distribution | 1 | 1995 | 33 | 0.010 |
Why?
| Patient Compliance | 1 | 1995 | 55 | 0.010 |
Why?
| Cell Line, Transformed | 1 | 1993 | 5 | 0.010 |
Why?
| Cell-Free System | 1 | 1991 | 1 | 0.010 |
Why?
| Lymphocyte Transfusion | 1 | 1991 | 1 | 0.010 |
Why?
| Mice, Nude | 1 | 1991 | 10 | 0.010 |
Why?
| DNA, Viral | 1 | 1991 | 13 | 0.010 |
Why?
| Disease Models, Animal | 1 | 1991 | 71 | 0.010 |
Why?
| Glucose | 1 | 1991 | 22 | 0.010 |
Why?
| Oxygen Consumption | 1 | 1991 | 18 | 0.010 |
Why?
| Aniline Compounds | 1 | 1990 | 1 | 0.010 |
Why?
| Mitogens | 1 | 1990 | 2 | 0.010 |
Why?
| Ionophores | 1 | 1990 | 3 | 0.010 |
Why?
| Xanthenes | 1 | 1990 | 2 | 0.010 |
Why?
| Indoles | 1 | 1990 | 3 | 0.010 |
Why?
| Ciprofloxacin | 1 | 1989 | 3 | 0.010 |
Why?
| Thalassemia | 1 | 1989 | 2 | 0.010 |
Why?
| Teratogens | 1 | 1988 | 4 | 0.010 |
Why?
| Biological Availability | 1 | 1987 | 8 | 0.000 |
Why?
| Mathematics | 1 | 1985 | 2 | 0.000 |
Why?
| Meningitis | 1 | 1985 | 3 | 0.000 |
Why?
| Hydrocephalus | 1 | 1985 | 8 | 0.000 |
Why?
| Infusions, Parenteral | 1 | 1985 | 5 | 0.000 |
Why?
| Myocardial Contraction | 1 | 1984 | 7 | 0.000 |
Why?
| Heart Rate | 1 | 1984 | 26 | 0.000 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|